FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A

The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with MPS IIIA, also known as Sanfilippo syndrome type A.